Clonal evolution, late events (relapse + clonal evolution), and survival rates following cyclophosphamide + cyclosporine. (A) Clonal evolution. The cumulative incidence of clonal evolution at 1 year was 22% (95% CI, 0-39%). (B) Late events. An additional 2 patients relapsed, bringing the total incidence of late events (relapse + clonal evolution) to 28% (95% CI, 4-46%) at 2 years. (C) Overall survival. The 2-year survival for this cohort was 72% (95% CI, 55-94%). Day 0 in this survival curve is the first day of cyclophosphamide. Dotted lines represent 95% CIs. See Figure 2 in the article by Scheinberg et al that begins on page 2820.